Acromegaly: Diagnostic pitfalls

Endocrinologist

Volumn 14, Issue 5, 2004, Pages 277-287

  Freda, Pamela U ^a  

^a Columbia Coll of Phys and Surgeons ^*  (United States)

Author keywords

Acromegaly; Growth hormone; IGF I

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; COMORBIDITY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HUMAN; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; REVIEW; SYSTEMATIC REVIEW;

EID: 4544351560     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000139007.95472.f8     Document Type: Review

References (115)

1. Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf). 1980;12:71-79.
2. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf). 1987;26:481-512.
3. Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore). 1994;73:233-240.
4. Swearingen B, Barker FG II, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83:3419-3426.
5. Beauregard C, Truong U, Hardy J, et al. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf). 2003;58:86-91.
6. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89:667-674.
7. Freda PU. Advances in the diagnosis of acromegaly. Endocrinologist. 2000;10:237-244.
8. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am. 1992;21:597-614.
9. Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med. 1994;121:478-483.
10. Kaltsas GA, Mukherjee JJ, Jenkins PJ, et al. Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab. 1999;84:2731-2735.
11. Lopez-Velasco R, Escobar-Morreale HF, Vega B, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab. 1997;82:1047-1053.
12. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg. 1998;89:353-358.
13. Freda PU, Reyes CM, Nuruzzaman AT, et al. Basal and glucose-suppressed GH levels less than 1 μg/L in newly diagnosed acromegaly. Pituitary. 2003;6:175-180.
14. Bates AS, Vanthoff W, Jones JM, et al. Does treatment of acromegaly affect life expectancy. Metab Clin Exp. 1995;44:1-5.
15. Freda PU, Post KD, Powell JS, et al. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab. 1998;83:3808-3816.
16. Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm IGF Res. 2003;13:171-184.
17. Celniker AC, Chen AB, Wert RM Jr, et al. Variability in the quantitation of circulating growth hormone using commercial immunoassays. J Clin Endocrinol Metab. 1989;68:469-476.
18. Levin PA, Chalew SA, Martin L, et al. Comparison of assays for growth hormone using monoclonal or polyclonal antibodies for diagnosis of growth disorders. J Lab Clin Med. 1987;109:85-88.
19. Reiter EO, Morris AH, MacGillivray MH, et al. Variable estimates of serum growth hormone concentrations by different radioassay systems. J Clin Endocrinol Metab. 1988;66:68-71.
20. Ebdrup L, Fisker S, Sorensen HH, et al. Variety in growth hormone determinations due to use of different immunoassays and to the interference of growth hormone-binding protein. Horm Res. 1999;1(suppl): 20-26.
21. Seth J, Ellis A, Al-Sadie R. Serum growth hormone measurements in clinical practice: an audit of performance from the UK National External Quality Assessment scheme. Horm Res. 1999;1(suppl):13-19.
22. Chapman IM, Hartman ML, Straume M, et al. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab. 1994;78:1312-1319.
23. De Marinis L, Mancini A, Bianchi A, et al. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients. Metabolism. 2002;51:616-621.
24. Dimaraki EV, Jaffe CA, DeMott-Friberg R, et al. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab. 2002;87:3537-3542.
25. Costa AC, Rossi A, Martinelli CE Jr, et al. Assessment of disease activity in treated acromegalic patients using a sensitive GH Assay: Should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab. 2002;87:3142-3147.
26. Hattori N, Shimatsu A, Kato Y, et al. Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly. J Clin Endocrinol Metab. 1990;70:771-776.
27. Bristow AF. International standards for growth hormone. Horm Res. 1999;1(suppl):7-12.
28. Ranke MB, Orskov H, Bristow AF, et al. Consensus on how to measure growth hormone in serum. Horm Res. 1999;1(suppl):27-29.
29. Melmed S, Jackson I, Kleinberg D, et al. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab. 1998;83:2646-2652.
30. Camacho-Hubner C. Assessment of growth hormone status in acromegaly: what biochemical markers to measure and how? Growth Horm IGF Res. 2000;10(suppl B):S125-129.
31. Jaffe CA, Barkan AL. Acromegaly. Recognition and treatment. Drugs. 1994;47:425-445.
32. Earll JM, Sparks LL, Forsham PH. Glucose suppression of serum growth hormone in the diagnosis of acromegaly. JAMA. 1967;201:628-630.
33. Freda PU, Landman RE, Sundeen RE, et al. Gender and age in the biochemical assessment of cure of acromegaly. Pituitary. 2001;4:163-171.
34. Frantz AG, Rabkin MT. Effects of estrogen and sex difference on secretion of human growth hormone. J Clin Endocrinol Metab. 1965;25:1470-1480.
35. Engstrom BE, Karlsson FA, Wide L. Gender differences in diumal growth hormone and epinephrine values in young adults during ambulation. Clin Chem. 1999;45:1235-1239.
36. van den Berg G, Veldhuis JD, Frolich M, et al. An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab. 1996;81:2460-2467.
37. Tonshoff B, Blum WF, Mehls O. Derangements of the somatotropic hormone axis in chronic renal failure. Kidney Int Suppl. 1997;58:S106-113.
38. Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab. 1987;64:51-58.
39. Pincus SM, Gevers EF, Robinson IC, et al. Females secrete growth hormone with more process irregularity than males in both humans and rats. Am J Physiol. 1996;270:E107-115.
40. Chang-DeMoranville BM, Jackson IM. Diagnosis and endocrine testing in acromegaly. Endocrinol Metab Clin North Am. 1992;21:649-668.
41. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85:526-529.
42. Zadik Z, Chalew SA, McCarter RJ Jr, et al. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab. 1985;60:513-516.
43. Hartman ML, Veldhuis JD, Thomer MO. Normal control of growth hormone secretion. Horm Res. 1993;40:37-47.
44. Vierhapper H, Heinze G, Gessl A, et al. Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism. 2003;52:181-185.
45. Duncan E, Wass JA. Investigation protocol: acromegaly and its investigation. Clin Endocrinol (Oxf). 1999;50:285-293.
46. Vinik A, Pimstone B, Buchanan-Lee B. Impairment of hyperglycemic induced growth hormone suppression in hyperthyroidism. J Clin Endocrinol Metab. 1968;28:1534-1538.
47. Becker MD, Cook GC, Wright AD. Paradoxical elevation of growth hormone in active chronic hepatitis. Lancet. 1969;2:1035-1039.
48. Kayath MJ, Russo EM, Dib SA, et al. Do impaired glucose tolerance and diabetes mellitus interfere with the interpretation of the growth hormone response to the oral glucose tolerance test? Braz J Med Biol Res. 1992;25:449-455.
49. Grecu EO, Walter RM Jr, Gold EM. Paradoxical release of growth hormone during oral glucose tolerance test in patients with abnormal glucose tolerance. Metabolism. 1983;32:134-137.
50. Pieters GF, Smals AG, Kloppenborg PW. Defective suppression of growth hormone after oral glucose loading in adolescence. J Clin Endocrinol Metab. 1980;51:265-270.
51. Holl RW, Bucher P, Sorgo W, et al. Suppression of growth hormone by oral glucose in the evaluation of tall stature. Horm Res. 1999;51:20-24.
52. Bates AS, Evans AJ, Jones P, et al. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clin Endocrinol (Oxf). 1995;42:417-423.
53. Dobrashian RD, O'Halloran DJ, Hunt A, et al. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diumal profiles and following oral glucose in acromegaly. Clin Endocrinol (Oxf). 1993;38:589-593.
54. Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994;41:95-102.
55. Kaltsas GA, Isidori AM, Florakis D, et al. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab. 2001;86:1645-1652.
56. Peacey SR, Shalet SM. Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly. Ann Clin Biochem. 2001;38:297-303.
57. Ho KY, Weissberger AJ. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol (Oxf). 1994;41:75-83.
58. Hartman ML, Veldhuis JD, Vance ML, et al. Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J Clin Endocrinol Metab. 1990;70:1375-1384.
59. Peacey SR, Toogood AA, Veldhuis JD, et al. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J Clin Endocrinol Metab. 2001;86:259-266.
60. Parfitt VJ, Flanagan D, Wood P, et al. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1. Clin Endocrinol (Oxf). 1998;49:647-652.
61. Clemmons DR, Underwood LE. Nutritional regulation of IGF-I and IGF binding proteins. Annu Rev Nutr. 1991;11:393-412.
62. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994;15:80-101.
63. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-34.
64. Clemmons DR, Van Wyk JJ. Factors controlling blood concentration of somatomedin C. Clin Endocrinol Metab. 1984;13:113-143.
65. Frystyk J, Ivarsen P, Stoving RK, et al. Determination of free insulin-like growth factor-I in human serum: comparison of ultrafiltration and direct immunoradiometric assay. Growth Horm IGF Res. 2001;11:117-127.
66. Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 1988;67:69-73.
67. Clemmons DR, Van Wyk JJ, Ridgway EC, et al. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979;301:1138-1142.
68. de Herder WW, van der Lely AJ, Janssen JA, et al. IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. Clin Endocrinol (Oxf). 1995;43:501-505.
69. Kim HJ, Kwon SH, Kim SW, et al. Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults. Horm Res. 2001;56:117-123.
70. Roelfsema F, Frolich M, Van Dulken H. Somatomedin-C levels in treated and untreated patients with acromegaly. Clin Endocrinol (Oxf). 1987;26:137-144.
71. van der Lely AJ, de Herder WW, Janssen JA, et al. Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis. J Endocrinol. 1997;155(suppl 1):S9-13; discussion S15-16.
72. Lamberts SW, Uitterlinden P, Schuijff PC, et al. Therapy of acromegaly with Sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'. Clin Endocrinol (Oxf). 1988;29:411-420.
73. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171-1177.
74. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358:1754-1759.
75. Jaquet P, Guibout M, Jaquet C, et al. Circadian regulation of growth hormone secretion after treatment in acromegaly. J Clin Endocrinol Metab. 1980;50:322-328.
76. Barreca A, Ciccarelli E, Minuto F, et al. Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly. Acta Endocrinol (Copenh). 1989;120:629-635.
77. Rieu M, Girard F, Bricaire H, et al. The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly. J Clin Endocrinol Metab. 1982;55:147-153.
78. Wass JA, Clemmons DR, Underwood LE, et al. Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly. Clin Endocrinol (Oxf). 1982;17:369-377.
79. Jasper H, Pennisi P, Vitale M, et al. Evaluation of disease activity by IGF-I and IGF binding protein-3 (IGFBP3) in acromegaly patients distributed according to a clinical score. J Endocrinol Invest. 1999;22:29-34.
80. Paramo C, Andrade O MA, Fluiters E, et al. Comparative study of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) level and IGF-I/IGFBP-3 ratio measurements and their relationship with an index of clinical activity in the management of patients with acromegaly. Metabolism. 1997;46:494-498.
81. Arafah BM, Rosenzweig JL, Fenstermaker R, et al. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly. J Lab Clin Med. 1987;109:346-354.
82. Lindholm J, Giwercman B, Giwercman A, et al. Investigation of the criteria for assessing the outcome of treatment in acromegaly. Clin Endocrinol (Oxf). 1987;27:553-562.
83. Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab. 2000;85:3132-3140.
84. Colao A, Cuocolo A, Marzullo P, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab. 2001;86:1551-1557.
85. Knappe G, Hesse V, Jahreis G, et al. Somatomedin-C in active and successfully treated acromegaly. Exp Clin Endocrinol. 1988;91:2-6.
86. Brockmeier SJ, Buchfelder M, Adams EF, et al. Acromegaly with 'normal' serum growth hormone levels. Clinical features, diagnosis and results of transsphenoidal microsurgery. Horm Metab Res. 1992;24:392-400.
87. Clemmons DR. Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Horm Res. 2001;2(suppl):73-79.
88. Melmed S. Confusion in clinical laboratory GH and IGF-I reports. Pituitary. 1999;2:171-172.
89. LeRoith D, Clemmons D, Nissley P, et al. NIH conference. Insulin-like growth factors in health and disease. Ann Intern Med. 1992;116:854-862.
90. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors in the fed and fasted states. J Clin Endocrinol Metab. 1982;55:999-1002.
91. Hall K, Hilding A, Thoren M. Determinants of circulating insulin-like growth factor-I. J Endocrinol Invest 1999;22:48-57.
92. Gama R, Labib M, Teale JD, et al. Acromegaly with a misleading normal plasma insulin-like growth factor 1. Ann Clin Biochem. 1989;26:102-103.
93. Strasburger CJ, Bidlingmaier M, Wu Z, et al. Normal values of insulin-like growth factor I and their clinical utility in adults. Horm Res. 2001;2(suppl):100-105.
94. Schalch DS, Kalayoglu M, Pirsch JD, et al. Serum insulin-like growth factors and their binding proteins in patients with hepatic failure and after liver transplantation. Metabolism. 1998;47:200-206.
95. Feld S, Hirschberg R. Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev. 1996;17:423-480.
96. Goldberg AC, Trivedi B, Delmez JA, et al. Uremia reduces serum insulin-like growth factor I, increases insulin-like growth factor II, and modifies their serum protein binding. J Clin Endocrinol Metab. 1982;55:1040-1045.
97. Frystyk J, Ivarsen P, Skjaerbaek C, et al. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int. 1999;56:2076-2084.
98. Wong NA, Ahlquist JA, Camacho-Hubner C, et al. Acromegaly or chronic renal failure: a diagnostic dilemma. Clin Endocrinol (Oxf). 1997;46:221-226.
99. Miell JP, Taylor AM, Zini M, et al. Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF-binding proteins. J Clin Endocrinol Metab. 1993;76:950-955.
100. Herlihy OM, Perros P. Elevated serum growth hormone in a patient with type 1 diabetes: a diagnostic dilemma. Diabetes Metab Res Rev. 2000;16:211-216.
101. Hilding A, Hall K, Wivall-Helleryd IL, et al. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab. 1999;84:2013-2019.
102. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, et al. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf). 1994;41:351-357.
103. Ghigo E, Aimaretti G, Gianotti L, et al. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol. 1996;134:352-356.
104. Dall R, Longobardi S, Ehmborg C, et al. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. J Clin Endocrinol Metab. 2000;85:4193-4200.
105. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 1991;72:374-381.
106. Cardim, HJ, Lopes CM, Giannella-Neto D, et al. The insulin-like growth factor-I system and hormone replacement therapy. Fertil Steril. 2001;75:282-287.
107. Gomez JM, Maravall FJ, Gomez N, et al. Interactions between serum leptin, the insulin-like growth factor-I system, and sex, age, anthropometric and body composition variables in a healthy population randomly selected. Clin Endocrinol (Oxf). 2003;58:213-219.
108. Parkinson C, Ryder WD, Trainer PJ. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab. 2001;86:5240-5244.
109. Clemmons DR, Underwood LE, Ridgway EC, et al. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am J Med. 1980;69:571-575.
110. Cozzi R, Barausse M, Lodrini S, et al. Estroprogestinic pill normalizes IGF-I levels in acromegalic women. J Endocrinol Invest. 2003;26:347-352.
111. Freda PU, Nuruzzaman AT, Reyes CM, et al. Significance of 'abnormal' nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab. 2004;89:495-500.
112. Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004;89:1613-1617.
113. Melmed S, Ezrin C, Kovacs K, et al. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med. 1985;312:9-17.
114. Thomer MO, Perryman RL, Cronin MJ, et al. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest. 1982;70:965-977.
115. Sano T, Asa SL, Kovacs K. Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr Rev. 1988;9:357-373.